"Having good market intelligence is no longer optional in this day and age"
Rakesh Pabbi - Senior Partner
As first announced in February, the Lloyd’s Lab will focus on designing technology-driven solutions to meet the unique and rapidly changing needs of the Lloyd’s market. The Lab will enable new concepts, ideas and products to be tested in a fast-track, fast-fail environment with the support and active involvement of Lloyd’s market participants.
Sweden’s consulting market grows the strongest to almost €1billion (€944million)
- Nordic region viewed as a global digital leader by consultants – as revenues from digital transformation work approaches €1billion...
The growth of the Nordics consulting market has continued to accelerate - increasing 5.7 per cent to reach a value of €2.77billion in 2017. All four countries in the region grew at a faster rate than in 2016, with Sweden—the region’s largest market—seeing the strongest growth rate of 6.9 per cent to €944million.
Despite the negative connotations that Uber's fatal self-driving crash brought to the technology one month ago, the sector is, nevertheless, attracting more and more capital bets and fueling excitement as time goes on, especially in China.
JDX Consulting, the global financial services firm, has today announced the consolidation of its subsidiaries: JDX Consulting, Fintech Solutions, base60 and JDX International to form JDX. This re-structure will simplify the global operating model, providing greater value to clients and stronger organisational alignment for its people, during this exciting period of growth.
Increasing female representation in top-paying jobs and high-growth industries could add more than $26 billion to Singapore's economy by 2025 - representing additional growth of 5 per cent per year.
In Europe, the centralised procedure allows a Marketing Authorisation Holder (MAH) to market a medicine across all EU Member States including Iceland, Liechtenstein and Norway on the basis of a single marketing authorisation application to the European Medicines Agency (EMA). Today, the great majority of new, innovative medicines pass through this procedure; ATMPs must be authorised in this way.
Accenture has acquired Certus Solutions in a bid to utilize the Oracle Cloud implementation partner in creating the next wave of "intelligent enterprises."
The tech giant said that Certus Solutions will become part of Accenture's Oracle practice, with a particular focus on shepherding clients towards Oracle Cloud applications.
There are many challenges in the pharmaceutical supply chain, from maintaining quality to security issues. Can blockchain provide the end-to-end visibility needed?
It’s a good time for the pharmaceutical industry. Whether you’re a manufacturer of clinical trial materials or prescription medicines ready for pharmacy shelves, business has been booming. In fact, pharma has spent the last 30 years as a consistently top-performing industry.
Last February, United Kingdom-based software developer Medopad announced it had signed 15 Chinese trade deals. CEO of Medopad Dan Vahdat commented that the new agreements would see the parties “work to improve patient care in China” and their technology used to contribute “towards China’s healthcare reform goals.”
IT firm Cognizant today said it has acquired privately-held Hedera Consulting, a move that will strengthen the former's consulting and digital transformation capabilities for clients in Belgium and the Netherlands.
May marks the 17th month since Sean Menke became CEO of Sabre, the travel technology company based in Southlake, Texas.
Menke inherited a company that may not have been in as good a shape as had been suggested by its stock valuation — which had nearly doubled from its 2014 initial public offering.
Global consulting firm McKinsey & Company is said to have helped the UK Government identify £813 million worth of savings in its procurement spending. According to a Freedom of Information request, the leading consultancy was paid £10 million for the cost-cutting advisory services provided to the Crown Commercial Service.
The volume of data being collected by industrial companies has increased exponentially. Enabled by IIoT sensors, high-performance computing and cloud technologies, analysis and predicting outcomes around complex problems has been made a reality in a way that conventional engineering, operations and maintenance technologies have not been able to in the past.
A QATARI consulting firm is opening a new office in Belfast, creating 22 jobs.
In a bid to grow its business across Europe, Excelledia Quality Consulting, headquartered in Doha, is opening an innovation centre in the city and aims to have all the new positions in place by the start of next year. It is the first inward investment to come from Qatar and it is hoped more will follow in the future.
Her Majesty The Queen today announced drug development consultancy, Artemida Pharma, as a recipient of the Queen's Award for Enterprise in the International Trade category.
Initial coin offerings have raised billions of dollars for startups while attracting criminals and authorities around the globe. Now, the young market may get some help cleaning up from the Big Four consulting firms.
Mark Douglas had no idea what five extra days off a year could do for his company.
It was January of 2017, and Douglas, CEO of the marketing and advertising company SteelHouse, announced to his team that every month without a three-day weekend would now come with a so-called "SteelHouse Day."
For one Friday or Monday each month, the entire company would shut down.
The Crown Commercial Service has commenced the second tender process to award firms a place on its Management Consultancy Framework. Management Consultancy Framework 2 (MCF2) is projected to be worth over £2 billion, and will pertain to business consultancy services; procurement, supply chain, and commercial consultancy services; complex and transformation consultancy services; and strategic consultancy services.
We have a deal—a preliminary one, at least.
Late Tuesday, after a fifth buyout offer from Takeda, Shire said the Japanese drugmaker had finally landed on a proposal worth recommending to shareholders. It's a cash-and-stock bid now worth $64 billion or so, about $4 billion more than its first offer.
The deal still has to be approved by both boards and is subject to due diligence. The U.K.'s takeover board, which has strict rules for the timing and disclosure of bids, extended a deadline to give Takeda and Shire until May 8 to wrap it up.
Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.
In per-share terms, Takeda would fork over 0.839 new Takeda shares and $30.33 in cash for each Shire share. Based on Takeda's share price at Monday's close, that's £49 per share, Shire said in a statement—and £5 per share more than its first bid.
That share price is a moving target, though; Takeda's stock plummeted by 7% on the news Wednesday morning.
Structured this way, the deal “seems to be much more of a merger,” Bernstein analyst Ronny Gal pointed out in a note to clients. Shire shareholders will receive 50% of the value of the combined company, and the companies will do reciprocal due diligence before any deal closes.
At least one analyst isn’t so sure Shire shareholders will be interested.
“Are SHPG shareholders willing to accept an offer that is in effect 44% cash and 56% equity?” Jefferies' David Steinberg wrote in a note to clients. While the latest bid is much more heavily weighted toward cash than Takeda's third bid—just 38% cash—“we still wonder if it is enough to satisfy SHPG shareholders, who would still bear some not insignificant risk going forward as ~50% owners of NewCo,” he wrote.
Gal, on the other hand, figures the deal will go through.
“The risk to the deal is unlikely in our view to come from Shire shareholders or anti-trust authorities,” he wrote, noting that its Takeda’s shareholders, not Shire’s., that have sent the stock downward throughout the bidding process. Still, he pegged the probability of the deal going through at between 80% and 90%.
“Short of Takeda stock price imploding a deal is likely,” he added.
Both analysts agree on one thing, though: Another bidder, which some industry watchers previously expected, probably won’t come out of the woodwork at this point.
“We expect Shire bankers to have left no stone unturned looking for other bidders,” Gal wrote, with Steinberg adding that “we continue to think any potential group of buyers to be very limited … it’s arguably less than a 50% chance that another suitor emerges.”
Sourced from FiercePharma
Baringa Partners has expanded its global presence with the opening of a new office in Sydney, Australia, aiming to replicate the success of its UK business which is currently rated the number one management consultancy in energy, utilities and the environment by the Financial Times. The Australian office, headed up by Peter Sherry and Brett Clark, will build on Baringa’s international experience and its position as the largest dedicated energy consulting practice in Europe, and will bring its full advisory capability to the Australian market.
